Nivolumab vs Upadacitinib

## Nivolumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Upadacitinib**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Upadacitinib**: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Upadacitinib — 9-14 hours.

## Chemical Properties

**Molecular Formula**: Nivolumab — N/A; Upadacitinib — C17H19F3N6O.

**Molecular Weight**: Nivolumab — N/A; Upadacitinib — 380.3700 g/mol.

**Type**: Nivolumab — Antibody; Upadacitinib — Small molecule.